Trials / Unknown
UnknownNCT04292340
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (estimated)
- Sponsor
- Shanghai Public Health Clinical Center · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.
Conditions
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-07-31
- Completion
- 2020-12-31
- First posted
- 2020-03-03
- Last updated
- 2020-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04292340. Inclusion in this directory is not an endorsement.